Findings

What do systematic reviews say?

9 questions · 9 findings · 2 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 44.4%GRADE not reported 0 · 0%Very low 5 · 55.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Gemcitabine vs vandetanib

Serious adverse events · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.79 [0.41, 1.52]
1 study · 115 participants
Very low

Gemcitabine plus S‐1 vs S‐1

Serious adverse events · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 1.05 [0.15, 7.1]
1 study · 90 participants
Very low

Gemcitabine plus cisplatin vs S‐1 plus cisplatin

Serious adverse events · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus vandetanib vs vandetanib

Serious adverse events · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus vandetanib changes serious adverse events compared with vandetanib (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.95 [0.52, 1.74]
1 study · 117 participants
Very low

Gemcitabine plus oxaliplatin vs best supportive care

Serious adverse events · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Serious adverse events · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

Serious adverse events · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 1.5 [0.66, 3.39]
1 study · 34 participants
Very low

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

Serious adverse events · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adjuvant S‐1 vs gemcitabine

Serious adverse events · people with resectable cholangiocarcinoma

1 finding from 1 review

Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Very low